346 related articles for article (PubMed ID: 26100603)
21. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
Schwartz S; Cornely OA; Hamed K; Marty FM; Maertens J; Rahav G; Herbrecht R; Heinz WJ
Med Mycol; 2020 Jun; 58(4):417-424. PubMed ID: 31613363
[TBL] [Abstract][Full Text] [Related]
22. New and investigational triazole agents for the treatment of invasive fungal infections.
De Sarro A; La Camera E; Fera MT
J Chemother; 2008 Dec; 20(6):661-71. PubMed ID: 19129062
[TBL] [Abstract][Full Text] [Related]
23. Isavuconazole: A new broad-spectrum azole. Part 2: pharmacokinetics and clinical activity.
Ledoux MP; Denis J; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):15-22. PubMed ID: 29551442
[TBL] [Abstract][Full Text] [Related]
24. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
Cecil JA; Wenzel RP
Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
[TBL] [Abstract][Full Text] [Related]
25. Posaconazole: an extended-spectrum triazole antifungal agent.
Schiller DS; Fung HB
Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
[TBL] [Abstract][Full Text] [Related]
26. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
Kovanda LL; Maher R; Hope WW
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
28. Isavuconazole: a role for the newest broad-spectrum triazole.
Slavin MA; Thursky KA
Lancet; 2016 Feb; 387(10020):726-8. PubMed ID: 26684608
[No Abstract] [Full Text] [Related]
29. Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.
Odds FC
Curr Opin Investig Drugs; 2006 Aug; 7(8):766-72. PubMed ID: 16955689
[TBL] [Abstract][Full Text] [Related]
30. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
Jenks JD; Salzer HJ; Prattes J; Krause R; Buchheidt D; Hoenigl M
Drug Des Devel Ther; 2018; 12():1033-1044. PubMed ID: 29750016
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.
Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL
Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396
[TBL] [Abstract][Full Text] [Related]
32. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
Pfaller MA; Rhomberg PR; Castanheira M
Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
[TBL] [Abstract][Full Text] [Related]
33. Isavuconazonium sulfate (Cresemba)--a new antifungal.
Med Lett Drugs Ther; 2016 Mar; 58(1490):37-8. PubMed ID: 26963156
[No Abstract] [Full Text] [Related]
34. Successful Isavuconazole therapy in a patient with acute invasive fungal rhinosinusitis and acquired immune deficiency syndrome.
Ahmed Y; Delaney S; Markarian A
Am J Otolaryngol; 2016; 37(2):152-5. PubMed ID: 26954873
[TBL] [Abstract][Full Text] [Related]
35. Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.
Zhang T; Shen Y; Feng S
Front Cell Infect Microbiol; 2022; 12():1049959. PubMed ID: 36530445
[TBL] [Abstract][Full Text] [Related]
36. Isavuconazonium: first global approval.
McCormack PL
Drugs; 2015 May; 75(7):817-22. PubMed ID: 25902926
[TBL] [Abstract][Full Text] [Related]
37. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacological profile of isavuconazole].
Azanza Perea JR; Sádaba Díaz de Rada B
Rev Iberoam Micol; 2018; 35(4):186-191. PubMed ID: 30477963
[TBL] [Abstract][Full Text] [Related]
39. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
[TBL] [Abstract][Full Text] [Related]
40. Isavuconazole: Case Report and Pharmacokinetic Considerations.
Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P
Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
